Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im P act of R esidual Inflammation Detected via Imaging T E chniques, D rug Levels and Patient Characteristics on the Outcome of Dose Taper I ng of Adalimumab in C linical Remission Rheumatoid Ar T hritis ( RA ) patients (PREDICTRA).

MLA

Emery, Paul, et al. “Design of a Phase IV Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Im P Act of R Esidual Inflammation Detected via Imaging T E Chniques, D Rug Levels and Patient Characteristics on the Outcome of Dose Taper I Ng of Adalimumab in C Linical Remission Rheumatoid Ar T Hritis ( RA ) Patients (PREDICTRA).” BMJ Open, vol. 8, no. 2, Feb. 2018, p. e019007. EBSCOhost, https://doi.org/10.1136/bmjopen-2017-019007.

APA

Emery, P., Burmester, G. R., Naredo, E., Zhou, Y., Hojnik, M., & Conaghan, P. G. (2018). Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im P act of R esidual Inflammation Detected via Imaging T E chniques, D rug Levels and Patient Characteristics on the Outcome of Dose Taper I ng of Adalimumab in C linical Remission Rheumatoid Ar T hritis ( RA ) patients (PREDICTRA). BMJ Open, 8(2), e019007. https://doi.org/10.1136/bmjopen-2017-019007

Chicago

Emery, Paul, Gerd R Burmester, Esperanza Naredo, Yijie Zhou, Maja Hojnik, and Philip G Conaghan. 2018. “Design of a Phase IV Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Im P Act of R Esidual Inflammation Detected via Imaging T E Chniques, D Rug Levels and Patient Characteristics on the Outcome of Dose Taper I Ng of Adalimumab in C Linical Remission Rheumatoid Ar T Hritis ( RA ) Patients (PREDICTRA).” BMJ Open 8 (2): e019007. doi:10.1136/bmjopen-2017-019007.